United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients

United Therapeutics Corporation UTHR has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary arterial hypertension (PAH).

• Related Content: In June FDA Accepted Tyvaso DPI Application Under Priority Review.
• United Therapeutics has developed Tyvaso DPI under a collaboration and license agreement with MannKind Corporation MNKD
• Data were presented at the European Respiratory Society (ERS) International Congress 2021.
• Tyvaso DPI is a next-generation dry powder formulation of Tyvaso (treprostinil) Inhalation Solution, currently under FDA review. 
• If approved, Tyvaso DPI is expected to provide a more convenient administration method than traditional nebulized Tyvaso therapy.
• The transition from nebulized Tyvaso to Tyvaso DPI demonstrated safety and tolerance with significant improvements in six-minute walk distance (6MWD) and other key factors.
• Three weeks after switching from Tyvaso to Tyvaso DPI, patients demonstrated improvements of 11.5 meters in 6MWD compared to baseline.
• Significant improvements were observed in overall satisfaction with the Tyvaso DPI inhaler.
• Significant improvements in PAH impacts were observed in physical impacts and cognitive/emotional impacts.
• Price Action: UTHR shares are down 1.02% at $208.66, while MNKD stock is up 1.91% at $4.81 during the market session on the last check Tuesday.